SELLAS Life Sciences Group, Inc. SLS
Set alert
9.68 USD -0.47 -4.68%
At close
9.70 +0.02 +0.21%
Pre-market · Nov 2, 8:00 AM ET
9.30 Day range 9.79
1.39 52-week range 15.88
- YTD
- +156.76%
- 1 year
- +431.87%
- Open
- 9.63
- Prev close
- 10.16
- Mkt cap
- 1.95B
- Vol
- 6.26M
- Avg vol
- 6.67M
- EPS
- -0.21
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.30
- High
- 9.79
- Forward P/E
- -93.40
- Beta
- 2.57
- Short ratio
- 10.31
- Inst. own
- 36.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 18, 2026
- 50-d avg
- 12.23
- 200-d avg
- 8.54
- 1y target
- 32.50
1D chart
Signals (68)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | 3:51 PM | 2 days ago |
| RSI: Overbought | 3:45 PM | 2 days ago |
| MACD: Buy Signal | 3:36 PM | 2 days ago |
| MACD: Sell Signal | 3:16 PM | 2 days ago |
| RSI: Overbought | 3:04 PM | 2 days ago |
| SMA: Bullish | 3:01 PM | 2 days ago |
| MACD: Buy Signal | 2:59 PM | 2 days ago |
| RSI: Oversold | 2:52 PM | 2 days ago |
| MACD: Sell Signal | 2:50 PM | 2 days ago |
| SMA: Bullish | 2:41 PM | 2 days ago |
| MACD: Buy Signal | 2:39 PM | 2 days ago |
| MACD: Sell Signal | 2:33 PM | 2 days ago |
| RSI: Oversold | 2:30 PM | 2 days ago |
| MACD: Buy Signal | 2:24 PM | 2 days ago |
| RSI: Oversold | 2:16 PM | 2 days ago |
| MACD: Sell Signal | 2:15 PM | 2 days ago |
| MACD: Buy Signal | 2:07 PM | 2 days ago |
| MACD: Sell Signal | 2:01 PM | 2 days ago |
| RSI: Oversold | 2:01 PM | 2 days ago |
| MACD: Buy Signal | 1:55 PM | 2 days ago |
| MACD: Sell Signal | 1:47 PM | 2 days ago |
| MACD: Buy Signal | 1:41 PM | 2 days ago |
| RSI: Oversold | 1:35 PM | 2 days ago |
| SMA: Bearish | 1:28 PM | 2 days ago |
| SMA: Bearish | 1:28 PM | 2 days ago |
| MACD: Sell Signal | 1:28 PM | 2 days ago |
| SMA: Bullish | 1:21 PM | 2 days ago |
| MACD: Buy Signal | 1:21 PM | 2 days ago |
| MACD: Sell Signal | 1:17 PM | 2 days ago |
| SMA: Bearish | 1:16 PM | 2 days ago |
| SMA: Bearish | 1:11 PM | 2 days ago |
| SMA: Bullish | 1:05 PM | 2 days ago |
| SMA: Bullish | 1:05 PM | 2 days ago |
| MACD: Buy Signal | 1:00 PM | 2 days ago |
| SMA: Bearish | 12:44 PM | 2 days ago |
| MACD: Sell Signal | 12:42 PM | 2 days ago |
| MACD: Buy Signal | 12:41 PM | 2 days ago |
| MACD: Sell Signal | 12:32 PM | 2 days ago |
| RSI: Overbought | 12:29 PM | 2 days ago |
| RSI: Overbought | 12:18 PM | 2 days ago |
| MACD: Buy Signal | 12:14 PM | 2 days ago |
| SMA: Bearish | 12:10 PM | 2 days ago |
| MACD: Sell Signal | 12:10 PM | 2 days ago |
| MACD: Buy Signal | 12:09 PM | 2 days ago |
| SMA: Bullish | 12:08 PM | 2 days ago |
| MACD: Sell Signal | 12:01 PM | 2 days ago |
| SMA: Bearish | 12:00 PM | 2 days ago |
| SMA: Bullish | 11:49 AM | 2 days ago |
| MACD: Buy Signal | 11:47 AM | 2 days ago |
| SMA: Bearish | 11:17 AM | 2 days ago |
| MACD: Sell Signal | 11:12 AM | 2 days ago |
| MACD: Buy Signal | 11:00 AM | 2 days ago |
| SMA: Bullish | 10:56 AM | 2 days ago |
| SMA: Bearish | 10:54 AM | 2 days ago |
| MACD: Sell Signal | 10:52 AM | 2 days ago |
| MACD: Buy Signal | 10:40 AM | 2 days ago |
| SMA: Bullish | 10:39 AM | 2 days ago |
| SMA: Bullish | 10:38 AM | 2 days ago |
| SMA: Bearish | 10:34 AM | 2 days ago |
| SMA: Bullish | 10:33 AM | 2 days ago |
| SMA: Bearish | 10:32 AM | 2 days ago |
| MACD: Sell Signal | 10:32 AM | 2 days ago |
| SMA: Bearish | 10:30 AM | 2 days ago |
| SMA: Bearish | 10:23 AM | 2 days ago |
| SMA: Bullish | 10:20 AM | 2 days ago |
| SMA: Bullish | 10:20 AM | 2 days ago |
| MACD: Buy Signal | 10:18 AM | 2 days ago |
| SMA: Bearish | 10:01 AM | 2 days ago |
Key statistics
- Market cap
- 1.89B
- Enterprise value
- 1.91B
- Trailing P/E
- 0.00
- Forward P/E
- -93.40
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 13.70
- EPS (TTM)
- -0.21
- Beta
- 2.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -16.38M
- Total cash
- 138.34M
- Total debt
- 737.00K
- Return on equity
- -39.63%
- Shares outstanding
- 201.95M
- Short % of float
- 26.73%
- 50-day average
- 12.23
- 200-day average
- 8.54
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 32.50 +235.7% upside
Now 9.68
- Target (low)
- 30.00
- Target (mean)
- 32.50
- Target (high)
- 35.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 18, 2026
Expected Nov 18, 2026. Consensus EPS estimate -0.05.
Financials — quick view
SLS Revenue — quarterly 0
SLS Net income — quarterly -9.61M
SLS EPS — quarterly -0.05
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2026 | Sep 30, 2026 | -0.05 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.045 | -0.05 | -0.01 | -11.11% |
| May 12, 2026 | Mar 31, 2026 | -0.06 | -0.05 | +0.01 | +16.67% |
| Mar 19, 2026 | Dec 31, 2025 | -0.06333 | -0.05 | +0.01 | +21.05% |
| Nov 12, 2025 | Sep 30, 2025 | -0.06333 | -0.06 | 0.00 | +5.26% |
| Aug 12, 2025 | Jun 30, 2025 | -0.08333 | -0.07 | +0.01 | +16.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | main | Buy | Buy |
| Jul 16, 2025 | Maxim Group | main | Buy | Buy |
| Nov 22, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 15, 2022 | Alliance Global Partners | main | — | Buy |
| Jun 28, 2022 | Cantor Fitzgerald | main | — | Overweight |
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sellaslifesciences.com
News
- 10 Health Care Stocks Whale Activity In Today’s Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- SELLAS Life Sciences Stock Stumbles: What's Going On?
- SELLAS Life Sciences Announces Its Pivotal Phase 3 Study Of Galinpepimut-S In Acute Myeloid Leukemia Participants Surpasses Pre-Specified 80th Event
- SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
Your note
Sign in to keep a note on SLS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNS JOHN THOMAS | Chief Financial Officer | Stock Award(Grant) | Jan 6, 2026 | 554,327 |
| CICIC DRAGAN | Officer | Stock Award(Grant) | Jan 6, 2026 | 557,805 |
| KALIN KATHERINE BACH | Director | Stock Award(Grant) | Jan 6, 2026 | 154,400 |
| SCHEINBERG DAVID A | Director | Stock Award(Grant) | Jan 6, 2026 | 73,082 |
| STERGIOU ANGELOS M | Chief Executive Officer | Stock Award(Grant) | Jun 15, 2026 | 1,759,180 |
| VAN NOSTRAND ROBERT L | Director | Stock Award(Grant) | Jan 6, 2026 | 82,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.46% | 15,070,302 | 140.76M | Jun 29, 2026 |
| State Street Corporation | 6.44% | 12,996,558 | 121.39M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.07% | 8,226,105 | 76.83M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.42% | 4,884,175 | 45.62M | Jun 29, 2026 |
| Anson Funds Management LP | 2.23% | 4,500,000 | 42.03M | Jun 29, 2026 |
| Jones Financial Companies, L.L.L.P. | 1.14% | 2,304,561 | 21.52M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 5,906,922 | 55.17M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.81% | 5,665,912 | 52.92M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.58% | 5,214,545 | 48.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06% | 2,134,837 | 19.94M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02% | 2,063,963 | 19.28M | Jul 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.93% | 1,880,069 | 17.56M | Sep 29, 2026 |